The current status in hematopoietic stem cell mobilization

J Clin Apher. 2015 Oct;30(5):273-80. doi: 10.1002/jca.21374. Epub 2015 Mar 19.

Abstract

Hemotopoietic stem cell mobilization with cytokines alone, has still been widely accepted as the initial attempt for stem cell mobilization. Chemotherapy based mobilization can be preferred as first choice in high risk patients or for remobilization. But mobilization failure still remains to be a problem in one third of patients. Salvage mobilization strategies have been composed to give one more chance to 'poor mobilizers'. Synergistic effect of a reversible inhibitor of CXCR4, plerixafor, with G-CSF has opened a new era for these patients. Preemptive approach in predicted poor mobilizers, immediate salvage approach for patients with suboptimal mobilization or remobilization approach of plerixafor in failed mobilizers have all been demonstrated convincing results in various studies. Alternative CXCR4 inhibitors, VLA4 inhibitors, bortezomib, parathormone have also been emerged as novel agents for mobilization failure.

Keywords: stem cell mobilization.

MeSH terms

  • Animals
  • Antigens, CD34 / analysis
  • Antineoplastic Agents / pharmacology
  • Benzylamines
  • Biological Factors / pharmacology
  • Bortezomib / pharmacology
  • Cyclams
  • Cytapheresis* / methods
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Hematopoietic Stem Cell Mobilization* / methods
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / physiology
  • Heterocyclic Compounds / pharmacology
  • Humans
  • Integrin alpha4beta1 / antagonists & inhibitors
  • Mice
  • Parathyroid Hormone / pharmacology
  • Receptors, CXCR4 / antagonists & inhibitors
  • Recombinant Proteins / pharmacology

Substances

  • Antigens, CD34
  • Antineoplastic Agents
  • Benzylamines
  • Biological Factors
  • CXCR4 protein, human
  • Cyclams
  • Heterocyclic Compounds
  • Integrin alpha4beta1
  • Parathyroid Hormone
  • Receptors, CXCR4
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Bortezomib
  • plerixafor